A lipid-anchored neurokinin 1 receptor antagonist prolongs pain relief by a three-pronged mechanism of action targeting the receptor at the plasma membrane and in endosomes
Nicholas A. Veldhuis(Australian Research Council), Daniel P. Poole(Monash University), Michelle L. Halls(Discovery Institute), Christopher J. H. Porter(Monash University), Joshua Conner(Australian Research Council), Arisbel B. Gondin(Monash University), Meritxell Canals(University of Nottingham), Nigel W. Bunnett(New York University), Jeffri S. Retamal(Universidad de Santiago de Chile), Stephen J. Hill(University of Nottingham), Priyank A. Shenoy(University of Queensland), Tim Quach(Australian Research Council), Cameron J. Nowell(Discovery Institute), Stephen J. Briddon(University of Nottingham), Holly R. Yeatman(Monash University), Luigi Aurelio(Australian Research Council), Thomas P. Davis(The University of Queensland), Bim Graham(Australian National University)
Cited by 29
Related Papers
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
|Nature Medicine|2000|931
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome
|Gastroenterology|2007|768
4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1
|Proceedings of the National Academy of Sciences|2007|762
A Decade of the Protein Corona
|ACS Nano|2017|651